NEXTBio Capital Management LP Portfolio
Auto-discovered active 13F filer.
SEC 13F CIK: 0002038158
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2026 · 22 positions · Total reported value $217.40M · Top-10 concentration 77.7% · Updated 2026-10-24
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
Turnover: 38.5% · 4 new · 4 cut · 2 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -4.2% · vs SPY -6.3% · Prev Value $217.40M — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -3.2% · vs SPY -5.4% · Latest Value $229.71M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q2 2026 13F filing, NEXTBio Capital Management LP disclosed 22 equity positions with a combined reported value of $217.40M. The filing implies a focused portfolio: its ten largest positions account for 77.7% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2026 were PTGX ($26.89M), STTK ($25.87M), CMPS ($25.13M). By sector, the heaviest allocations are Health Care 100.0%. Versus the prior quarter, allocation shifted toward Health Care (+16.0pp) and away from Other (-16.0pp).
Versus the prior quarter, NEXTBio Capital Management LP opened 4 new positions, trimmed 4 and fully exited 2, a turnover rate of 38.5% of positions. The portfolio's overlap with the prior quarter was 70% of names.
The largest new positions opened in Q2 2026 were PHVS ($3.74M), BIOA ($2.47M), LBRX ($2.22M).
Of the 2 positions fully exited versus the prior quarter, the largest were TERN ($31.87M), CMPX ($4.49M), OCS ($3.98M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2026)
Insider Transactions (Form 4)
Latest NEXTBio Capital Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
NEXTBio Capital Management LP, based in Austin, TX, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 22 positions worth $217.40M in total. HoldingsHub carries 3 quarters of its filings (Q4 2025–Q2 2026).
Firm Snapshot
- Headquarters: AUSTIN, TX, United States
- SEC registration: 801-136876 (status: Approved), registered 2026-07-23
- Regulatory AUM (Form ADV): $305.21M as of 2026-07-07
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 6 private funds, of which 1 hedge funds
- Website: nextbiocapital.com
Portfolio Structure
- 22 positions · $217.40M reported value (Q2 2026)
- Top 10 holdings = 77.7% of reported value
- Largest position: PTGX (PROTAGONIST THERAPEUTICS INC) at 12.4%
- Average position size: $9.88M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 3 new, 7 added, 4 reduced, 5 exited
- 8 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
219.33K | $26.89M | 12.37% | Reduce | |
| 2 |
|
3.73M | $25.87M | 11.90% | Add | |
| 3 |
|
1.78M | $25.13M | 11.56% | Reduce | |
| 4 |
|
312.50K | $16.77M | 7.71% | Add | |
| 5 |
|
889.16K | $16.37M | 7.53% | Reduce | |
| 6 |
|
131.76K | $14.63M | 6.73% | Add | |
| 7 |
|
89.91K | $13.74M | 6.32% | Add | |
| 8 |
|
183.22K | $11.06M | 5.09% | Hold | |
| 9 |
|
426.74K | $10.83M | 4.98% | Hold | |
| 10 |
|
706.12K | $7.65M | 3.52% | Add | |
| 11 |
|
1.79M | $6.76M | 3.11% | Add | |
| 12 |
|
372.86K | $6.71M | 3.09% | Hold | |
| 13 |
|
107.22K | $6.23M | 2.87% | Add | |
| 14 |
|
131.07K | $5.07M | 2.33% | Hold | |
| 15 |
|
1.31M | $4.99M | 2.30% | Hold | |
| 16 |
|
52.66K | $3.85M | 1.77% | Hold | |
| 17 |
|
108.06K | $3.74M | 1.72% | New | |
| 18 |
|
183.36K | $3.48M | 1.60% | Hold | |
| 19 |
|
100.73K | $2.47M | 1.14% | New | |
| 20 |
|
68.25K | $2.22M | 1.02% | New | |
| 21 |
|
119.06K | $1.58M | 0.73% | Reduce | |
| 22 |
|
157.83K | $1.36M | 0.63% | Hold | |
FAQ
What did NEXTBio Capital Management LP buy in 2026-Q2?
In its 2026-Q2 13F filing, NEXTBio Capital Management LP reported 22 equity positions worth $217.40M in aggregate; its largest disclosed positions were PTGX ($26.89M), STTK ($25.87M), CMPS ($25.13M).
How large is NEXTBio Capital Management LP's portfolio?
NEXTBio Capital Management LP reported $217.40M of long equity holdings across 22 positions as of 2026-Q2. Top-10 holdings account for 77.7% of reported value.
What is NEXTBio Capital Management LP's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.